“No to the forced replacement therapies to all patients in treatment for some serious diseases rheumatological
The doctor must be guaranteed the freedom with prescribed values that must always be shared with the patient.
“And this is the message that is contained in a letter that the National Association of Rheumatism Sufferers Onlus (ANMAR) has today sent to the President of the Republic Sergio Mattarella.
The letter follows on from the decision of the five Regions (Piemonte, Lazio, Sardegna, Valle d’aosta and Veneto) to join together for the purchase of a drug used in the treatment of rheumatoid arthritis and psoriatic arthritis.
“It was a race to the bottom that has led to savings, but will require the use of the drug to a lower cost for the patients of the five major regions of italy – says Silvia Tonolo, National President of ANMAR -. As representatives of the rheumatism sufferers we would like to clarify that we have nothing against the use of biosimilars that are ‘similar’ to the drug ‘originator’ and that cost less.
We wish, however, that there are no impositions from on high, dictated only and exclusively by issues of budget. Throughout the national territory, a patient should always have the medication that is most suitable.
And this choice must be done only and exclusively by the attending physician. It is a right essential and also recognized by our Constitution.
Precisely for this reason we decided to address directly to the Head of the State. ” “We also want to remember that the switch, i.
the transition from the use of a drug, biological originator to a biosimilar, can have harmful consequences for the health of a patient rheumatic – adds Tonolo -. . In recent years our association has been, repeatedly, to denounce the attempts of some regions to impose this clinical practice. The savings for the various regional health systems – concludes – may not be obtained on the skin of patients who are already dealing with serious disabling diseases such as those rheumatological”.